Engflag

Lox -2%

Quick links to important sections

Lox -2%

Lox -2%_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lox -2%

What is Lox -2%?

Lox -2% is a topical or injectable medication containing lidocaine hydrochloride at a 2% concentration. It belongs to the class of medications known as local anesthetics. This pharmacological agent is primarily used to induce a reversible loss of sensation in a specific, localized area of the body.

Mechanism of Action

The primary function of Lox -2% is to block the conduction of nerve impulses. It achieves this by inhibiting the movement of sodium ions through the cell membranes of neurons. When sodium channels are stabilized, the nerve cannot send electrical signals to the brain, which prevents the perception of pain in the treated area.

Common Applications

Lox -2% is utilized across various medical and dental settings to facilitate procedures that might otherwise cause discomfort. Its applications include:

  • Minor Surgical Procedures: Numbing the skin or mucous membranes before stitches, small incisions, or biopsies.
  • Dental Work: Providing localized anesthesia for fillings, extractions, or other oral surgeries.
  • Diagnostic Procedures: Assisting in the comfort of patients undergoing certain internal examinations or catheter insertions.
  • Surface Anesthesia: Reducing sensitivity on the skin or within the mouth and throat before the application of more invasive instruments.

Characteristics

As a 2% solution, the medication provides a standard strength that balances efficacy with a localized profile. The effects typically begin within minutes of application or injection and last for a duration sufficient to complete most minor medical interventions. Unlike general anesthesia, Lox -2% allows the patient to remain fully conscious while ensuring the targeted site remains insensitive to pain.

Regulatory References

  1. WHO Essential Medicines List (Lidocaine Entry)
  2. NIH/NLM Drug Information Portal (Lidocaine)
  3. MedlinePlus Lidocaine and Prilocaine Topical

What side effects are possible with Lox -2%?

Possible Side Effects and Safety Information

The safety profile of topical lidocaine, the active ingredient in Lox -2%, is characterized primarily by localized application site reactions and the potential for systemic toxicity, as documented in official regulatory sources.

Regulatory Classification of Adverse Reactions

The most common adverse reactions are typically localized to the application site and are classified as Skin and Subcutaneous Tissue Disorders. These may include manifestations such as irritation, erythema (redness), and pruritus (itching). These local effects are generally described as transient.

Classification Examples of Documented Effects
Common Irritation, Erythema, Pruritus, Burning sensation
Extremely Rare Hypersensitivity reactions, Anaphylactoid reactions

Systemic Safety Concerns

Systemic adverse reactions are generally associated with plasma levels that exceed the therapeutic threshold due to excessive use or high absorption. These serious adverse reactions often involve the Nervous System and Cardiovascular System.

  • Serious Adverse Reactions: These may include signs of Systemic Toxicity such as seizures, convulsions, respiratory arrest, cardiovascular collapse, and cardiac arrest. A serious hematologic concern is the potential for methemoglobinemia.

  • Time-Related Patterns: Drowsiness may be an early sign of increasing blood levels. Regulatory information notes that repeated doses carry a risk of increased blood levels due to the slow accumulation of the drug.

Safety Considerations and Restrictions

Official labels advise that caution is necessary for specific populations, including older adults, pediatric patients, and those with severe hepatic impairment, as they may be more susceptible to adverse effects. The medication is contraindicated in individuals with a known history of sensitivity to amide-type local anesthetics. Furthermore, a key restriction noted in regulatory documents is to avoid application to broken, inflamed, or severely traumatized skin due to the significantly increased risk of systemic absorption and associated toxic symptoms.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Lox -2% (lidocaine topical) results from excessive systemic absorption, leading to documented systemic toxicity that affects key physiological systems.

Documented Manifestations and Systems

  • Central Nervous System (CNS): Toxicity often begins with signs such as lightheadedness, dizziness, tinnitus, or confusion. These manifestations may rapidly progress to more severe signs, including tremors, twitching, and ultimately, convulsions (seizures) or respiratory arrest.
  • Cardiovascular System (CVS): Serious cardiac effects are typically depressant in nature, characterized by bradycardia (slow heart rate), hypotension (low blood pressure), and cardiovascular collapse, which can lead to cardiac arrest.
  • Methemoglobinemia: A documented complication that involves a reduced capacity for oxygen transport. Signs include cyanotic skin discoloration (pale, gray, or blue-colored skin) and shortness of breath.

When Immediate Medical Help is Required

If any signs of systemic toxicity are observed, immediate medical attention should be sought. This mandatory regulatory action is required for severe outcomes like seizure activity, shallow breathing, loss of consciousness, or the appearance of methemoglobinemia symptoms. No specific antidote is known for lidocaine-induced systemic toxicity; management focuses on symptomatic and supportive treatment, including maintaining ventilation. Patients with severe hepatic or cardiac impairment, and pediatric patients (especially infants), are noted to be at increased risk of systemic toxicity.

Therapeutic Uses of Lox -2%

What Lox -2% Treats: Main Uses and Benefits

Lox -2% is a topical preparation used in areas where short-term symptomatic assistance is needed, primarily by providing a localized numbing effect. This type of medication helps by reducing sensitivity at the application site.

Symptom Relief and Supportive Comfort

This medication is commonly used to address symptoms related to physical discomfort, such as minor cuts, insect bites, or abrasions. It is also relevant for managing symptoms related to inflammatory or irritative states, including pronounced burning, stinging, and persistent itching. By easing these manifestations, it contributes to improved comfort during periods of heightened symptoms.

This topical anesthetic is relevant for easing symptoms and is used to offer a temporary loss of sensation. This supportive relief is often applied in scenarios where supportive symptom management is appropriate, such as prior to minor skin-level events. This use assists with maintaining functional stability during temporary strain.

“The application of Lox -2% supports the management of acute, localized symptoms by providing short-term, temporary relief from surface discomfort.”

Summary of Relief: Relief for Localized Pain and Irritation This medication is commonly used to address groups of symptoms that may appear suddenly, offering targeted support for acute discomfort and skin irritations.

Eligibility and Restrictions for Use

Eligibility for Lox -2% (Lidocaine HCl 2% Jelly)

Official regulatory documents establish clear restrictions regarding who can and cannot use Lox -2%. The medication is contraindicated in patients with a documented history of hypersensitivity or allergy to local anesthetics of the amide type, such as lidocaine, or to any other component of the jelly. Individuals with pre-existing conditions of severe shock or heart block must also not use this medicine.

Use is restricted based on the application site's condition. The jelly should not be used on mucosa that is infected and/or severely traumatized.

Special caution and dosage reduction are required for certain vulnerable patient groups. Children, elderly individuals, debilitated patients, and those who are acutely ill are typically eligible for reduced doses only, commensurate with their age and physical status, due to increased susceptibility to potential systemic effects. While not a formal contraindication, its use requires heightened monitoring in patients with severely impaired hepatic function. Eligibility status for pregnancy and lactation is not defined as a formal contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes clinically relevant interactions with Lox-2% (Lidocaine/Lignocaine) as documented in official regulatory sources. Interactions are categorized by their effect on drug levels or pharmacologic action.

Documented Pharmacokinetic Interactions

Lox-2% is metabolized primarily by CYP3A4 enzymes. Co-administration with inhibitors of this enzyme may reduce its metabolic clearance, leading to increased systemic exposure and potential for elevated plasma concentrations. Specific substances documented to increase Lox-2% levels include Cimetidine and Propranolol, which inhibit systemic clearance, and potent CYP3A4 Inhibitors (e.g., Amprenavir, Ritonavir).

Pharmacodynamic and Chemical Interactions

Co-administration with other Antiarrhythmic Drugs (e.g., Amiodarone, Quinidine, IV Phenytoin) may result in additive effects on cardiac electrophysiology, increasing the risk of rhythm disturbances. Use with Tramadol may increase the risk of CNS depression. A separate risk exists when Lox-2% is combined with other agents that cause Methemoglobinemia (e.g., Prilocaine or Sodium Nitrate), which increases the potential for this blood condition.

Interaction-Related Restrictions and Considerations

Classification Interacting Agents Practical Implication
Contraindicated Ergot-type Oxytocic Drugs (with Epinephrine formulation) Must not be co-administered.
Use with Caution Hepatic Impairment Increased susceptibility to toxicity due to impaired clearance.
Use with Caution MAOIs, Tricyclic Antidepressants (with Epinephrine formulation) Risk of severe hypertension; avoidance is advised.

No explicit dose separation times with food or other products are mandated in regulatory labeling for this active ingredient.

Mechanism of Action

Lidocaine's mechanism involves the creation of a reversible block in the electrical signal transmission within peripheral nerve pathways.

Specific Blockade of Voltage-Gated Sodium Channels

The core of Lidocaine's action is the direct, physical inhibition of Voltage-Gated Sodium Channels ( NaV) found in nerve membranes. The active ingredient accesses the channel's inner pore and obstructs the flow of sodium ions ( Na^+). This blockade prevents the influx of Na^+, an essential step for nerve cell electrical activation, leading to membrane stabilization. This is a use-dependent mechanism, preferentially blocking rapidly firing nerve fibers.

Interruption of Peripheral Signal Conduction

By halting the flow of Na^+ ions, the drug prevents the rapid depolarization needed to generate an action potential (electrical nerve impulse). The resulting conduction block interrupts the signaling pathway at the site of application. This cascade prevents electrical message transmission from the periphery to the central nervous system, producing the physiological consequence of a reversible absence of nerve conduction by disabling signal propagation.

Constraint in Acidic Physiological States

A key limitation of the drug's mechanism is its dependency on the surrounding pH. The drug must be in its uncharged, lipid-soluble form to cross the nerve cell membrane to reach its intracellular target. In tissue with acidosis (common during active inflammation or infection), the chemical balance shifts, greatly reducing the available uncharged form. This hinders drug penetration and reduces the effectiveness of the mechanism of nerve signal interruption at the application site.

Dosage and Administration Information

How to Use Lox -2% – Official Administration Guidelines

This section outlines the formalized usage principles for lidocaine 2% preparations, such as gels or jellies.

Administration Scope and Limits

The preparation is administered via the topical route to achieve localized anesthesia, primarily on mucosal surfaces like the urethra or as an anesthetic lubricant for the external surface of certain medical devices.

The total quantity of lidocaine hydrochloride administered is governed by a strict maximum dose of 600 mg in any single dosing period, defining the limit for adult procedural use. Repeat applications should occur no sooner than 12 hours after the previous dose.

Feature Guideline
Standard Dosing Volume Ranges from 3 mL to 5 mL (female urethra) up to 30 mL (full male urethral procedure).
Timing Requirement 5 to 10 minutes must elapse after administration for the anesthetic effect to become adequate before a procedure begins.
Handling Any unused portion must be discarded after the initial application.

Population-Specific Use and Procedural Constraints

Reduced doses are employed for elderly, acutely ill, or debilitated patients, with the dose determined based on their physical status. For pediatric patients under the age of ten, the total amount of lidocaine must not exceed 4.5 mg/kg of body weight.

Procedurally, the preparation must not be introduced into the inner lumen of medical devices, nor should it be used to lubricate stylettes. This constraint ensures proper administration relative to the device's function.

Connection to the Official Use Protocol

The official instructions establish a structured protocol that links administration to a specific therapeutic window, emphasizing precise dosing volumes and mandatory timing. This procedural sequence strictly governs the quantity and frequency of use, ensuring the application is correctly executed relative to the planned medical procedure.

Recent Clinical Evidence

Research evidence / Overview of studies for Lox -2%

Evidence for Localized Numbing of Mucous Membranes

Research has examined the use of topical lidocaine (the active ingredient in Lox -2%) in controlled clinical trials and regulatory evaluations focusing on studies evaluating a temporary, localized loss of sensation during minor procedures involving the mouth, pharynx, or urinary tract. The trials primarily focused on outcomes related to physical discomfort, using standardized scales to measure the measured change in pain intensity before and during the procedure. Studies monitored and reported patterns of short-term, localized changes in sensation, with data showing patterns related to an onset occurring within minutes following application, and the measured duration of effect being short-lived.

Research Evidence for Acute Pain and Discomfort Relief

The evidence base for using topical lidocaine to address outcomes linked to inflammatory or irritative states from minor cuts, insect bites, or abrasions includes systematic reviews and post-marketing observational data. Research explored short-term symptom changes and patient-reported discomfort using comparisons to placebo. Trials and observations described patterns in patient-reported discomfort scores monitored during the study period. Findings were mixed or showed heterogeneity when the data were compiled across various studies that used different concentrations or formulations of the active ingredient.

Areas of Uncertainty and Remaining Research Gaps

Direct, dedicated randomized controlled trials using the specific 2% concentration solution for very minor, everyday acute discomforts are often limited. As a result, the existing evidence is limited because it is often extrapolated from studies of higher-concentration products, such as patches, that were developed for chronic or neuropathic pain. This means data certainty appears lower in some areas where evidence is generalized. Furthermore, long-term effects are not fully established in the research literature, as the follow-up periods in most key studies were limited to the immediate duration of use.

Key Studies & References

  1. World Health Organization Model List of Essential Medicines – Lidocaine
  2. Topical anesthetics for pain relief: a review of the clinical effectiveness and guidelines (CADTH Rapid Response Report Summary)
  3. NICE Guideline NG46: Local anaesthetics for minor procedures

Frequently Asked Questions (FAQ)

Common questions about Lox -2% (FAQ)

Q: Is it safe to use this product while pregnant or breastfeeding?

Official product information notes that animal studies did not show evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Official documents describe the use of this product during pregnancy as appropriate only when the potential benefit is considered greater than the potential risk to the fetus. It is not known whether the drug passes into human milk, and the label indicates that official guidance advises caution regarding use while breastfeeding.

Q: Is this product absorbed into the bloodstream?

Yes, regulatory documents indicate that lidocaine can be absorbed into the bloodstream after being applied topically to mucous membranes. The amount absorbed depends on several factors, including the area of application, the dose used, and the duration of exposure. Once absorbed, the drug is processed by the liver and eliminated by the body.

Q: Does this product interact with ibuprofen or other NSAIDs?

The official product labeling for this topical solution does not specifically list common NSAIDs (Nonsteroidal Anti-inflammatory Drugs), such as ibuprofen, as known interacting drugs. However, the label does include a warning that certain other medicines, particularly those classified as oxidizing agents, may increase the potential for a serious blood condition called methemoglobinemia.

Q: Can my 15-year-old child use this product for a sore throat?

Regulatory information provides instructions for patients over 12 years of age or those who meet a minimum weight requirement. Regulatory guidance requires the solution to be expelled after use, rather than swallowed, in order to limit the potential for systemic absorption. Official guidelines specify use based on body weight and age.

Q: Is this medicine available over-the-counter or does it require a prescription?

According to the product's official prescribing information, Lox -2% is labeled as 'Rx ONLY'. This regulatory classification means the product requires a prescription from a licensed healthcare provider for dispensing.

Q: Can this be used long-term for chronic pain?

The official labeling does not provide guidance on the use of this product for extended periods to manage chronic pain. Regulatory information highlights that repeated doses may lead to a slow buildup of the drug in the bloodstream, which could increase the risk of serious side effects. The product is approved for short-term, topical anesthesia of irritated membranes.

Q: Is this product safe for children under 2 years old?

The product label includes a specific regulatory Warning about life-threatening and fatal events in infants and young children when lidocaine is used for certain non-approved purposes, such as teething pain. Official documents state that for patients under three years of age, the medication is only recommended for the prescribed indication and requires direct supervision by a healthcare professional.

How should Lox -2% be stored and disposed of?

How to Store and Dispose of Lox -2% (Lidocaine Viscous 2% Solution)

Official regulatory guidelines strictly govern the storage and disposal of this solution to maintain its quality and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically below 25 C (77 F).
Protection Keep the container tightly closed, protected from light, and strictly do not freeze (prohibited).
Handling Shake the liquid well before each use and keep in the original container.

Disposal and Safety

This medication must be stored out of the reach of children and pets immediately after use to prevent accidental ingestion. Do not use the product past the labeled expiry date. For disposal, unused or expired solution should not be poured down a drain or mixed with household trash. Consult a pharmacist for proper disposal instructions, following local and national environmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lox -2% found in:

A-Z Index: